AstraZeneca's (AZN.US) Tagrisso small molecule combination therapy has been approved again.
According to the Zhitong Finance APP, AstraZeneca (AZN.US) announced today that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) combined with pemetrexed and platinum chemotherapy has been approved in the European Union for first-line treatment of advanced epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC) in adult patients who have exon 19 deletion or exon 21 (L858R) mutation. Tagri
Express News | First-line treatment for advanced cancer! The small molecule combination therapy of Astrazeneca has been approved again.
What the U.K. Election Means for Oil Stocks and Other Sectors -- Barrons.com
By Brian Swint U.K. voters gave the biggest election victory to the Labour Party since former Prime Minister Tony Blair's landslide win in 1997. If history is anything to go by, that could be a boon
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
Investors in AstraZeneca (LON:AZN) Have Seen Strong Returns of 115% Over the Past Five Years
The European Commission Approves AstraZeneca's Tagrisso (Osimertinib) With Pemetrexed And Platinum-Based Chemotherapy As 1st-line Treatment For Advanced EGFR-Mutated Non-small Cell Lung Cancer Whose Tumors Have Exon 19 Deletions Or Exon 21 Mutations
The European Commission Approves AstraZeneca's Tagrisso (Osimertinib) With Pemetrexed And Platinum-Based Chemotherapy As 1st-line Treatment For Advanced EGFR-Mutated Non-small Cell Lung Cancer Whose T
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment
AstraZeneca (AZN.L, AZN.ST) said Friday the European Union approved Tagrisso plus pemetrexed and platinum-based chemotherapy as a first-line treatment for adults with advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
BenevolentAI: Appointment of Adviser
LONDON--(BUSINESS WIRE)--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of
Morgan Stanley Starts Absci at Overweight, Cites AI Theme
Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)
Sanofi's blockbuster drug Dupixent has been approved in Europe to treat pulmonary diseases.
Zhītōng Cáijīng APP learned that sanofi (SNY.US) heavyweight drug Dupixent has been approved for use in European patients with chronic lung disease, opening up a new path of growth. According to a statement from the company on Wednesday, European regulators became the first in the world to approve the vaccine as an additional treatment for patients with chronic obstructive pulmonary disease (some with high levels of white blood cells). In two milestone studies, the drug reduced disease progression, improved lung function, and improved quality of life. The decision makes Dupixent a treatment option for approximately 220,000 adult CO patients in the European Union.
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices.
Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices.
AstraZeneca Hits 4-week Low
Eli Lilly, Novo Under Pressure as Biden Urges Lower Drug Prices
AstraZeneca (AZN) Receives a Hold From Jefferies
Express News | JEFFERIES: Raised the target price of AstraZeneca from $71 to $74.
Express News | AstraZeneca : Jefferies Raises Target Price to $74 From $71
AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment
The European Medicines Agency (EMA) has accepted AstraZeneca Plc's (NASDAQ:AZN) marketing authorization application for sipavibart for pre-exposure prophylaxis (prevention) of COVID-19 in immunocompro